[INSERT YOUR NAME/LOGO HERE]
DATE
NAME
ADDRESS
CITY, STATE ZIP
Dear [NAME]:
As you know, chronic sinusitis leads to difficulty breathing, facial pain or headache, and reduced sense of
smell and taste – greatly impacting quality of life. The condition is common, affecting 31 million people in
the U.S., according to the National Center for Health Statistics.
I wanted to let you know about a technology available in [CITY] for chronic sinusitis patients.
The PROPEL® mometasone furoate implant was developed to improve quality of life for patients with
chronic sinusitis by maintaining the openings created during sinus surgery. Applying principles of coronary
drug-eluting stents to sinusitis sufferers, the spring-like implants gradually deliver an advanced steroid with
anti-inflammatory properties directly to the sinus lining, then dissolve. The result is improved surgical
outcomes, reducing the need for additional surgical procedures and for systemic steroids, which can have
serious side effects1.
The clinical data supporting PROPEL is unique in the field of ENT. Level 1-A clinical evidence has been
published proving that use of the product in sinus surgery provides a statistically significant reduction in the
need for additional medication and surgical procedures and also reduces post-operative scarring and
inflammation that can compromise the benefit of the surgery. Safety and efficacy of the PROPEL
mometasone furoate implant has been studied in three prospective clinical trials conducted in the United
States, with a total of 205 patients enrolled1. For more information, visit www.PROPELOPENS.com.
This is a significant breakthrough for patients and an advancement in the surgical procedure. While sinus
surgery is effective in relieving symptoms, some patients’ symptoms return. To improve the outcome of a
successful operation, oral steroids are prescribed to reduce swelling and scarring. PROPEL provides antiinflammatory benefits without the common side effects of oral steroids.
The PROPEL steroid-releasing implant is currently available in select U.S. markets. As an early adopter, I
can attest to the implant’s positive results, as I have seen a number of my own patients benefit significantly
from this treatment.
I’d enjoy the opportunity to meet with you to discuss how we might work together to provide options for
patients in the area who may be good candidates for endoscopic sinus surgery. Together, we can work to
improve their quality of life with the improved surgical outcomes made possible by the PROPEL implant.
All the best,
[ADD SIGNATURE]
NAME
TITLE
PRACTICE
1 Han JK, Marple BF, Smith TL et al. IFAR. 2012; 2:271-279.
The PROPEL Sinus Implant is intended for use following ethmoid sinus surgery to maintain patency. For more information consult your
physician or visit www.intersectENT.com to view information including indications, contraindications, warnings, precautions and adverse
events. Caution: Federal law (USA) restricts this product to sale by or on the order of a physician.
PROPEL® is a registered trademark of Intersect ENT, Inc.
MPM 00005 Rev. B